Adverse Outcomes and Mortality in Liver Transplant Using MRI-Based Muscle Assessment Score

What this Trial Is About

This research aims to explore the relationship between muscle composition, measured by an MRI-based Muscle Assessment Score (MAsS), and negative outcomes in people being evaluated for liver transplant. Sarcopenia, or loss of muscle volume and function, is common in end-stage liver disease and is linked to worse health outcomes and higher risk of death. The study also seeks to understand how muscle health interacts with donor liver characteristics to affect transplant success and survival. Participants will undergo MRI scans during their liver transplant evaluation, where the MAsS will be added to the standard MRI to assess muscle volume and fat infiltration. This score combines measures of muscle size and fat content to provide a detailed picture of muscle health. The study will use these MRI assessments to identify patients at high risk of adverse outcomes, both before and after transplant, over a one-year period. During the study, participants' muscle health and transplant outcomes will be monitored through MRI and clinical follow-up for one year. Researchers will evaluate changes in the MAsS while waiting for transplant and record adverse events and mortality. This approach aims to provide a standardized, objective measurement to better predict risks in liver transplant candidates and improve understanding of factors impacting transplant success.

Adverse Outcomes and Mortality in Liver Transplant